Difference between revisions of "Allopurinol (Zyloprim)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 15: | Line 15: | ||
*'''Brand names:''' Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway | *'''Brand names:''' Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 22:15, 13 June 2018
General information
Class/mechanism: Xanthine oxidase inhibitor.
Route: PO/IV
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
No known antineoplastic properties. Used for tumor lysis syndrome treatment/prophylaxis.
History of changes in FDA indication
- 8/19/1966: Initial FDA approval
Also known as
- Brand names: Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway